Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449046
Status:
COMPLETED
Last Update Posted:
2015-05-06
First Post:
2007-03-16
Brief Title:
Clinical Assessment Of GW815SF SalmeterolFluticasone PropionateHFA MDI In Pediatric Patients With Bronchial Asthma -A Long Term 24-week Study-
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Clinical Assessment of GW815SF SalmeterolFluticasone Propionate HFA MDI in Pediatric Patients With Bronchial Asthma -A Long Term 24-week Study-
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the long-term 24-week safety and efficacy of GW815SF Salmeterolfluticasone propionateHFA MDI 50100mcgadministered as 2 inhalations of 2550mcg bid in pediatric patients with bronchial asthma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None